Overview
I am a physician-scientist with clinical expertise in the pathologic diagnosis of genitourinary tumors including tumors of the prostate, bladder, kidney and testis. Another area of interest is gynecologic tumors. In my research laboratory we study prostate cancer, focusing on molecular mechanisms of carcinogenesis and tumor progression, as well as biomarkers, imaging and novel therapeutic strategies. In addition to patient care and research, I am also passionate about education. I have trained numerous residents, fellows, graduate students and postdocs.
Current Appointments & Affiliations
Johnston-West Distinguished Professor of Pathology
·
2018 - Present
Pathology,
Clinical Science Departments
Chair
·
2016 - Present
Pathology,
Clinical Science Departments
Professor of Pathology
·
2016 - Present
Pathology,
Clinical Science Departments
Professor of Pharmacology and Cancer Biology
·
2017 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Neuroendocrine Tumor as a Somatic-Type Malignancy in Metastatic Teratoma.
Journal Article Int J Surg Pathol · December 2025 Testicular germ cell tumors represent less than 1% of all cancer diagnoses in men. Postpubertal-type teratomas are a form of nonseminomatous germ cell tumor derived from 2 or more embryonic germ cell layers. Rarely, these tumors have been shown to develop ... Full text Link to item CiteInternational Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.
Journal Article Am J Surg Pathol · December 1, 2025 Working Group 1 at ISUP's Cancer Precursors meeting (September 2024) evaluated 5 putative precursors of invasive prostate cancer: high-grade prostatic intraepithelial neoplasia (HGPIN), intraductal carcinoma (IDC), atypical intraductal proliferation (AIP), ... Full text Link to item CiteRevisiting the role of metabolic reprogramming as a contributor to prostate cancer disease progression.
Journal Article Chin Med J (Engl) · November 21, 2025 Prostate cancer (PCa) is one of the most common malignancies worldwide, and metabolic reprogramming plays a crucial role, particularly in tumor progression and therapeutic resistance. As PCa progresses into advanced stages, such as castration-resistant pro ... Full text Link to item CiteRecent Grants
2/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2025 - 2029Understanding and targeting epigentic regulation of immune evasion in prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2029View All Grants
Education, Training & Certifications
New York University ·
1991
Ph.D.
Anhui Medical University (China) ·
1983
M.D.